Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Botanix Pharmaceuticals
- 25 Oct 2019 Status changed from active, no longer recruiting to completed.
- 01 Aug 2019 According to a Botanix Pharmaceuticals media release, patient treatment expected to complete in 3Q CY2019.
- 31 May 2019 Status changed from recruiting to active, no longer recruiting.